Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Effects of calcium channel blockers on visual field progression in glaucoma patients
(Image credit: AdobeStock) Researchers from UK and Italian institutions investigated the association between the effects of calcium channel blockers and the rate of visual field (VF) progression in patients with glaucoma. First author Giovanni Montesano, MD, PhD, and colleagues reported…
Sandoz and Regeneron reach agreement over biosimilar dispute
(Image Credit: AdobeStock) Sandoz and Regeneron Pharmaceuticals have announced an agreement settling all patent disputes between the 2 companies relating to the US Food and Drug Administration (FDA)-approved Sandoz aflibercept biosimilar. Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv)…
UnitedHealthcare updates Glaucoma Surgical Treatments policy
(Image Credit: AdobeStock/gguy) UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to include goniotomy, trabeculotomy, canaloplasty (ab interno), combined canaloplasty (ab interno), and trabeculotomy procedures when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataracts…
Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa
(Image Credit: AdobeStock/Dmitrii Kotin) Beacon Therapeutics recently revealed topline data results for 2 of the company’s phase 2 trials—SKYLINE and DAWN, both investigating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).1 The data was presented during the 2025…
Amir Kashani on biomarkers for Alzheimer disease
(Image credit: AdobeStock/Pixel Matrix) Amir H. Kashani, MD, PhD, is a professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland. In an interview with Ophthalmology Times, Kashani discussed a research paper on OCT-A angiography’s…
Opus Genetics doses first patient in LYNX-3, phase 3 trial of phentolamine ophthalmic solution 0.75%
(Image Credit: AdobeStock/svetlanais) Opus Genetics has dosed the first patient in LYNX-3, its pivotal phase 3 clinical trial of phentolamine ophthalmic solution 0.75% in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Night-vision disturbances, which…
Contivue port delivery platform for nAMD receives CE mark
(Image credit: ©Symbiot/AdobeStock) The European Union has granted the EU CE mark to Roche’s port delivery platform, Contivue.1 This platform contains Susvimo (ranibizumab injection) 100 mg/mL, which is currently under review with the European Medicines Agency (EMA) for the treatment…
Creation of OpZira Inc. announced following Alcon’s acquisition of LumiThera
(Image credit: AdobeStock) The company OpZira Inc. has launched to advance ophthalmic diagnostics. The company plans to deliver innovative technologies with the ability to enhance the detection and monitoring of ocular disease, which can empower clinicians. Clark Tedford, PhD, President…
Ophthalmic Devices Market Surges to USD 100.2 Billion by 2033, Propelled by 6.4% CAGR
\n \n The Ophthalmic Devices Market is witnessing robust expansion driven by rising demand for advanced eye care solutions, growing prevalence of vision disorders, and a rapidly aging population. Technological advancements such as AI-driven diagnostics, minimally invasive surgical systems, and…
Outlook Therapeutics requests Type A meeting with FDA following second CRL for ONS-5010
(Image Credit: AdobeStock) Outlook Therapeutics has requested a Type A meeting with the US Food and Drug Administration following the agency issuing a complete response letter (CRL) to its biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment…